Christopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, Murad Alam, James S Andersen, Daniel Berg, Glen M Bowen, Richard T Cheney, Gregory A Daniels, L Frank Glass, Roy C Grekin, Kenneth Grossman, Susan A Higgins, Alan L Ho, Karl D Lewis, Daniel D Lydiatt, Kishwer S Nehal, Paul Nghiem, Elise A Olsen, Chrysalyne D Schmults, Aleksandar Sekulic, Ashok R Shaha, Wade L Thorstad, Malika Tuli, Marshall M Urist, Timothy S Wang, Sandra L Wong, John A Zic, Karin G Hoffmann, Anita Engh

Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.